# Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient

> **NCT00002025** · NA · COMPLETED · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Cytomegalovirus Infections
- Cytomegalovirus Retinitis
- HIV Infections

## Interventions

- **DRUG:** Ganciclovir

## Key facts

- **NCT ID:** NCT00002025
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002025, "Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT00002025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*